Highly Regarded Veterinary Marketing Executive to Join KindredBio’s Board
SAN FRANCISCO, California, (January 22, 2013) – Kindred Biosciences, Inc., (KindredBio) a biotechnology company focused on developing therapies for companion animals, today announced that Mr. Ervin Veszprémi will be joining the company’s Board of Directors.
Mr. Veszprémi previously served as the Head and VP of Global Marketing for Novartis Animal Health, one of the largest animal health companies in the world, where he was responsible for all veterinary products for Novartis worldwide. Prior to that, he was Country Head of Ciba-Geigy Animal Health, Spain.
Mr. Veszprémi is currently the CEO of Medichem, a leading manufacturer of active pharmaceutical ingredients to pharmaceutical companies worldwide. Mr. Veszprémi holds a physiology degree from University of British Columbia and has studied management at Harvard Business School and Stanford.
“We are delighted to welcome Mr. Veszprémi to KindredBio’s board,” stated Richard Chin, M.D., CEO of KindredBio. “Mr. Veszprémi brings extraordinary experience and insight about the veterinary market to the board.”
“I am looking forward to working with the KindredBio team,” stated Mr. Veszprémi. “KindredBio is a very promising company in a growing market and is well positioned to become a leader in this field.”
“Best Medicines for Our Best Friends”
KindredBio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, KindredBio is committed to bringing the very best science and medicine to companion animals.
Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date.
Lucentis® is a registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc.